An Open label, Two Arm, Randomized, Comparative Clinical Study to Evaluate the Efficacy and Safety of Cystone GNX tablet in chronic and recurrent UTI - Cys_GNX

The Himalaya Drug Company0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Adult male and female subjects aged >=18 to <= 65 years presenting atleast two of the following UTI symptoms as described in table1
•Three or more episodes of recurrent UTI in the past 12 months.
•UTI as diagnosed by urine culture more than 105 CFU/mL
•Subjects willing to sign informed consent and follow the study procedure.
•Subjects who has not participated in any similar kind of clinical study in the last one month.

•History of neurogenic bladder, pelvic irradiation or chemical cystitis, presence of urethral, pelvic, or rectal carcinoma, benign or malignant bladder tumors, tuberculous cystitis.
•Kidney Infection
•Pre-existing urolithiasis condition
•Pre-existing systemic disease: cardiac, neurological, renal or hepatic dysfunction.
•Antibacterial drug therapy for UTI during the previous 72 hours
•Patients with suspected or confirmed prostatitis
•Patients with renal transplantation or ileal loops
•History of urinary tract structural abnormalities.
•Any recent history of trauma to the pelvis or urinary tract.
•Pregnant & breast-feeding women.

发起方